| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | -0.0022 | 0.9 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.0022 | 0.9 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.0018 | 0.9 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | -0.0019 | 0.9 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | 0.0022 | 1 |
| mRNA | Carboplatin | CTRPv2 | pan-cancer | AAC | 0.0022 | 1 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.0034 | 1 |
| mRNA | selumetinib:UNC0638 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0019 | 1 |
| mRNA | BIRB 0796 | FIMM | pan-cancer | AAC | -0.01 | 1 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.0019 | 1 |